Thursday, November 12, 2026America’s Trusted News SourceFollow: X · Facebook · Bluesky

USA Pulse News

BREAKING · POLITICS · WORLD · SPORTS
LIVE
BREAKING
News

White House Drops FDA Nominee Heidi Overton a Day Before Senate Vote

Advertisement
Advertisement
The FDA headquarters building in Silver Spring, Maryland.

The White House has withdrawn Dr. Heidi Overton's nomination to lead the Food and Drug Administration, a day before a Senate committee was due to vote on advancing her. A White House official confirmed the decision on Tuesday 17 November, hours after Axios first reported it.

The Senate Health, Education, Labor and Pensions (HELP) Committee had been scheduled to vote on Wednesday 18 November on whether to send Overton's nomination to the full Senate. A senior administration official told Axios that Overton "lacks the support on the Hill to move forward with her confirmation."

The maths had turned against her. With Democrats expected to oppose her, Overton needed the votes of all 12 Republicans on the 21-member committee to advance. A single defection would have sunk it — and several Republicans had spent weeks signalling doubts.

Overton during her confirmation process.

Committee chairman Senator Bill Cassidy of Louisiana, a physician, had been the most pointed critic. Before Overton's confirmation hearing in September, he wrote on social media that he had "strong concerns" about her nomination, saying her lack of managerial experience left her poorly prepared to lead the agency. During the hearing he pressed her on vaccine safety and criticised her support for a Trump-backed plan to split combination childhood vaccines into separate doses. On the day of the withdrawal, Cassidy still said he remained undecided.

He was not alone. Senator Susan Collins of Maine told NBC News last week she was undecided and had "not taken a position," while Senator Lisa Murkowski of Alaska declined to say how she would vote. Collins had raised concerns about the FDA's authorisation of fruit-flavoured vaping products; Murkowski had concerns about the agency's approach to the abortion pill mifepristone.

Overton's September hearing had already exposed the fault lines running through her nomination. Senators pressed her on vaccines, abortion and flavoured vapes, and her candidacy became entangled in tensions between the "Make America Healthy Again" movement led by Health Secretary Robert F. Kennedy Jr. and more traditional conservative circles; Calley Means, who recently left his post as one of Kennedy's top advisers, publicly criticised her.

A Senate committee hearing room in session.

Trump nominated Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, on 19 August. Her nomination followed the departure of former FDA Commissioner Marty Makary, who resigned in May. The FDA has now been without a Senate-confirmed commissioner for six months; attorney Kyle Diamantas has led it on an acting basis since then.

Portrait of Dr. Heidi Overton.
Second view of the FDA headquarters entrance.

Attention now turns to who Trump picks next. Reuters reported that the White House is weighing Senator Roger Marshall of Kansas, a former obstetrician who recently lost re-election, as a replacement. Republicans are racing to confirm Trump's pending nominees before Democrats take the Senate in January, and it is unclear whether a new FDA nominee could advance before then. Whoever takes the job will inherit the FDA's safety review of mifepristone, which is due to finish in March.

Sources: USA TODAY; Reuters; Axios; CNN; CBS News; Medical Economics; The Straits Times; The Economic Times; Fierce Pharma; The Hill; STAT.

Advertisement